Influenza vaccine quadrivalent - Changchun Institute of biological Products

Drug Profile

Influenza vaccine quadrivalent - Changchun Institute of biological Products

Latest Information Update: 02 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator China National Biotec Group
  • Developer Changchun Institute of Biological Products; China National Biotec Group
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 01 Dec 2015 Launched for Influenza virus infections (Prevention) in China prior to December 2015
  • 01 Dec 2015 Changchun Institute of Biological Products initiates enrolment in a phase IV trial for Influenza virus infections (In Infants, In children, In adolescents) in China (ChiCTR-PPR-15007470)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top